News
As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...
Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...
With millions of Americans prescribed GLP-1 drugs, researchers warn of catastrophic risks ignored by Big Pharma.
About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...
Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...
As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...
Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.
Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...
Like semaglutide, the new drug known as ecnoglutide is glucagon-like peptide-1 receptor agonist. In simple terms, they both ...
Health insurance will grow more expensive in many corners of the market in 2026, and coverage may shrink. That could leave ...
16h
Korea JoongAng Daily on MSNWegovy prescriptions near 400,000 as experts concerned over widespread use, health risks
Prescriptions for popular weight-loss drug Wegovy have soared in Korea, reaching nearly 400,000 just eight months after its launch. But doctors and health officials warn of reckless use far beyond the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results